Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study
Journal of Cachexia, Sarcopenia and Muscle · 2026
DOI: 10.1002/jcsm.70240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Sung Hye Kong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Hauptthemen laut MEDLINE: Sarcopenia, Proteomics, Proteome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI), Ministry of Health and Welfare, Republic of Korea, National Institute of Health (NIH).
Abstract (Originalsprache)
Background
Sarcopenia is an age‐related condition characterized by progressive muscle mass, strength and physical performance declines, contributing to frailty and adverse health outcomes. Despite increasing interest in molecular biomarkers, longitudinal data with external validation are limited.
Methods
This study applied high‐throughput proteomic analysis to identify and validate biomarkers associated with sarcopenia progression in two independent prospective cohorts. The discovery cohort ( n = 171) was classified into three groups: (1) nonsarcopenic at both baseline and the 2‐year follow‐up; (2) newly developed sarcopenia; and (3) persistently sarcopenic. The validation cohort ( n = 93) was followed up for 2 years. Plasma proteomic profiling was conducted using data‐independent acquisition (DIA) mass spectrometry. For the validation cohort, targeted quantification (Hyper Reaction Monitoring‐DIA) and immunoassays were employed to verify key findings. Statistical analyses included multivariable regression and pathway enrichment analysis.
Results
In the discovery cohort, 102 proteins were differentially expressed between groups ( p < 0.05). Compared to the stable nonsarcopenic group, individuals who developed sarcopenia demonstrated significant APOA1 (fold change −1.42, p < 0.001) and KLKB1 downregulation and LECT2 upregulation. Those who remained sarcopenic exhibited persistent B2M (+1.58, p < 0.001), S100A9 and LYZ elevation. We identified seven robust protein signatures (LRG1, CST3, TIMP1, C2, ITIH1, AMBP and LYZ) that showed consistent significant associations with sarcopenia components in both cohorts. LRG1 and TIMP1, CST3 and C2 were reproducibly associated with muscle strength, physical performance and muscle mass, respectively. Pathway enrichment analyses consistently highlighted LXR/RXR signalling, acute phase response signalling and complement cascade activation as central mechanisms across these domains.
Conclusion
This study identified and validated plasma protein signatures and pathways associated with sarcopenia progression. Complement activation, acute inflammatory response and lipid dysregulation emerged as central mechanisms. These robustly validated biomarkers may represent targets for early detection and intervention strategies in sarcopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea.
- Department of Health Sciences and Technology, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
- Department of Preventive Medicine and Public Health, Ajou University School of Medicine, Suwon, Republic of Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
ORCID-Profile: Sung Hye Kong, Dohyun Han
Förderung
- Korea Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI)
- Ministry of Health and Welfare, Republic of Korea
- National Institute of Health (NIH)
- National Research Foundation of Korea, Republic of Korea
- Seoul National University Bundang Hospital
- Korean Endocrine Society of Convergence Research Award 2023
- Korea Health Industry Development Institute
- National Institutes of Health
Zitieren
APA
Kong, S. H., Jeon, O. H., Kim, J. Y., Kim, M., Kim, J., Park, S. S., Chang, H. C., Won, C. W., & Han, D. (2026). Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70240
Vancouver
Kong SH, Jeon OH, Kim JY, Kim M, Kim J, Park SS, et al. Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70240
BibTeX
@article{Kong2026,
author = {Kong, Sung Hye and Jeon, Ok Hee and Kim, Ji Yeon and Kim, Miji and Kim, Jinhee and Park, Seung Shin and Chang, Hak Chul and Won, Chang Won and Han, Dohyun},
title = {Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
doi = {10.1002/jcsm.70240}
}
EUVIMED